Lisata Therapeutics Inc Financials

LSTA

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Lisata Therapeutics Inc (LSTA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Lisata Therapeutics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.97x

For every $1 of reported earnings, Lisata Therapeutics Inc generates $0.97 in operating cash flow (-$19.4M OCF vs -$20.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

$1.0M

10Y CAGR-25.1%

Lisata Therapeutics Inc generated $1.0M in revenue in fiscal year 2024.

EBITDA

-$22.2M

YoY+12.9%

Lisata Therapeutics Inc's EBITDA was -$22.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.9% from the prior year.

Free Cash Flow

N/A

Net Income

-$20.0M

YoY+4.1%

Lisata Therapeutics Inc reported -$20.0M in net income in fiscal year 2024. This represents an increase of 4.1% from the prior year.

EPS (Diluted)

$-2.40

YoY+7.0%

Lisata Therapeutics Inc earned $-2.40 per diluted share (EPS) in fiscal year 2024. This represents an increase of 7.0% from the prior year.

Cash & Debt

$16.2M

YoY-28.3%

5Y CAGR+2.9%

10Y CAGR-1.7%

Lisata Therapeutics Inc held $16.2M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

YoY+3.2%

Lisata Therapeutics Inc had 8M shares outstanding in fiscal year 2024. This represents an increase of 3.2% from the prior year.

Gross Margin

N/A

Operating Margin

-2240.9%

10Y CAGR-1919.0pp

Lisata Therapeutics Inc's operating margin was -2240.9% in fiscal year 2024, reflecting core business profitability.

Net Margin

-1998.5%

10Y CAGR-1692.6pp

Lisata Therapeutics Inc's net profit margin was -1998.5% in fiscal year 2024, showing the share of revenue converted to profit.

Return on Equity

N/A

R&D Spending

$11.3M

YoY-11.0%

5Y CAGR+1.0%

10Y CAGR-9.0%

Lisata Therapeutics Inc invested $11.3M in research and development in fiscal year 2024. This represents a decrease of 11.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

LSTA Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$1.0M	$0	$0	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$11.3M-11.0%	$12.7M-2.5%	$13.1M-26.1%	$17.7M+91.1%	$9.3M-14.3%	$10.8M
SG&A Expenses	$12.1M-6.9%	$13.0M-8.3%	$14.1M+23.2%	$11.5M+16.0%	$9.9M+6.4%	$9.3M
Operating Income	-$22.4M+12.8%	-$25.7M+55.4%	-$57.6M-98.3%	-$29.1M-51.7%	-$19.1M+4.7%	-$20.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	$0
Income Tax	-$798K+65.8%	-$2.3M+6.0%	-$2.5M-64.4%	-$1.5M+86.1%	-$10.9M	$0
Net Income	-$20.0M+4.1%	-$20.8M+61.6%	-$54.2M-97.4%	-$27.5M-237.0%	-$8.2M+57.9%	-$19.4M
EPS (Diluted)	$-2.40+7.0%	$-2.58+75.4%	$-10.47-40.5%	$-7.45	$-0.53	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$0-100.0%	$70K	$0-100.0%	$1.0M	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.0M-13.0%	$2.3M-13.4%	$2.6M-11.8%	$3.0M+13.4%	$2.6M-19.7%	$3.2M+7.6%	$3.0M-10.9%	$3.4M
SG&A Expenses	$2.5M-8.6%	$2.7M-17.3%	$3.2M+8.2%	$3.0M+2.6%	$2.9M-13.0%	$3.4M+11.6%	$3.0M+16.6%	$2.6M
Operating Income	-$4.4M+9.3%	-$4.9M+16.7%	-$5.8M-18.1%	-$4.9M+10.4%	-$5.5M+16.3%	-$6.6M-9.6%	-$6.0M-1.0%	-$6.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0+100.0%	-$962K	$0	$0+100.0%	-$798K	$0	$0
Net Income	-$4.2M+8.8%	-$4.7M+1.4%	-$4.7M-2.5%	-$4.6M+8.6%	-$5.0M+6.6%	-$5.4M-0.7%	-$5.4M-2.0%	-$5.3M
EPS (Diluted)	$-0.49+9.3%	$-0.54+1.8%	$-0.550.0%	$-0.55+9.8%	$-0.61+6.2%	$-0.65+1.5%	$-0.66-1.5%	$-0.65

LSTA Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$35.0M-36.0%	$54.7M-25.1%	$73.0M-24.7%	$97.0M+169.5%	$36.0M+32.6%	$27.2M
Current Assets	$34.6M-35.9%	$53.9M-25.0%	$71.9M-25.3%	$96.2M+172.2%	$35.3M+36.0%	$26.0M
Cash & Equivalents	$16.2M-28.3%	$22.6M-29.7%	$32.2M+30.5%	$24.6M+49.3%	$16.5M+17.7%	$14.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$900K	$0	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.7M-16.4%	$6.8M+1.3%	$6.7M+34.0%	$5.0M+33.2%	$3.8M-43.0%	$6.6M
Current Liabilities	$5.6M-14.8%	$6.6M+3.2%	$6.4M+41.1%	$4.5M+29.0%	$3.5M-41.3%	$6.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$29.6M-38.6%	$48.1M-27.7%	$66.6M-27.8%	$92.3M+183.9%	$32.5M+56.1%	$20.8M
Retained Earnings	-$548.1M-3.8%	-$528.1M-4.1%	-$507.2M-12.0%	-$453.0M-6.5%	-$425.6M-2.0%	-$417.4M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$21.8M-13.5%	$25.2M-13.2%	$29.0M-17.2%	$35.0M-17.8%	$42.6M-11.8%	$48.2M-11.8%	$54.7M-5.8%	$58.1M
Current Assets	$21.6M-13.3%	$24.9M-13.0%	$28.6M-17.2%	$34.6M-17.6%	$42.0M-11.7%	$47.6M-11.8%	$53.9M-5.8%	$57.2M
Cash & Equivalents	$19.0M+12.8%	$16.8M-16.7%	$20.2M+24.7%	$16.2M-42.7%	$28.3M+29.8%	$21.8M-3.5%	$22.6M-30.3%	$32.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$502K+0.2%	$501K-33.2%	$750K-16.7%	$900K	N/A	N/A	$0	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.6M+5.8%	$4.4M+13.0%	$3.9M-31.8%	$5.7M+24.2%	$4.6M-16.8%	$5.5M-19.2%	$6.8M+26.3%	$5.4M
Current Liabilities	$4.6M+5.9%	$4.3M+13.3%	$3.8M-32.2%	$5.6M+25.9%	$4.5M-16.4%	$5.3M-19.1%	$6.6M+28.4%	$5.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$17.4M-17.4%	$21.0M-17.1%	$25.4M-14.3%	$29.6M-22.7%	$38.2M-11.0%	$43.0M-10.7%	$48.1M-9.1%	$53.0M
Retained Earnings	-$561.7M-0.8%	-$557.4M-0.8%	-$552.8M-0.9%	-$548.1M-1.8%	-$538.5M-0.9%	-$533.5M-1.0%	-$528.1M-1.0%	-$522.7M

LSTA Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$19.4M+3.4%	-$20.0M+5.4%	-$21.2M+4.8%	-$22.2M-152.1%	-$8.8M+53.3%	-$18.9M
Capital Expenditures	N/A	$0-100.0%	$285K+375.0%	$60K+200.0%	$20K	$0
Free Cash Flow	N/A	-$20.0M+6.6%	-$21.5M+3.8%	-$22.3M-152.2%	-$8.8M+53.2%	-$18.9M
Investing Cash Flow	$13.2M+31.0%	$10.1M-65.1%	$28.9M+152.7%	-$54.9M-654.4%	-$7.3M-134.0%	$21.4M
Financing Cash Flow	-$206K-153.5%	$385K+271.9%	-$224K-100.3%	$85.3M+359.0%	$18.6M+1470.6%	$1.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$3.3M+15.5%	-$4.0M+26.8%	-$5.4M-19.3%	-$4.5M+14.3%	-$5.3M+24.8%	-$7.0M-72.7%	-$4.1M-13.6%	-$3.6M
Capital Expenditures	$0	$0-100.0%	$28K	$0	$0	$0	$0	$0
Free Cash Flow	-$3.3M+15.5%	-$4.0M+27.1%	-$5.4M-115.6%	-$2.5M+52.3%	-$5.3M+24.8%	-$7.0M-72.7%	-$4.1M-13.6%	-$3.6M
Investing Cash Flow	$5.2M+919.8%	$505K-94.6%	$9.4M+579.0%	$1.4M-88.1%	$11.7M+82.0%	$6.4M+212.6%	-$5.7M-146.6%	$12.3M
Financing Cash Flow	$353K+451.6%	$64K+378.3%	-$23K+76.0%	-$96K-400.0%	$32K+122.5%	-$142K-691.7%	$24K+500.0%	-$6K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

LSTA Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-2240.9%	N/A	N/A	N/A	N/A	N/A
Net Margin	-1998.5%	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-57.1%-19.0pp	-38.1%+36.2pp	-74.3%-45.9pp	-28.3%-5.7pp	-22.6%+48.7pp	-71.3%
Current Ratio	6.16-2.0	8.18-3.1	11.26-10.0	21.27+11.2	10.08+5.7	4.35
Debt-to-Equity	0.19+0.1	0.14+0.0	0.10+0.0	0.05-0.1	0.12-0.2	0.32
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-6954.3%	N/A	-494.9%	N/A	N/A	N/A	N/A
Net Margin	N/A	-6655.7%	N/A	-461.0%	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-19.5%-1.0pp	-18.5%-2.2pp	-16.3%-3.1pp	-13.2%-1.3pp	-11.8%-0.6pp	-11.2%-1.4pp	-9.8%-0.8pp	-9.1%
Current Ratio	4.72-1.0	5.77-1.7	7.52+1.4	6.16-3.3	9.42+0.5	8.92+0.7	8.18-3.0	11.15
Debt-to-Equity	0.27+0.1	0.21+0.1	0.15-0.0	0.19+0.1	0.120.0	0.13-0.0	0.14+0.0	0.10
FCF Margin	N/A	-5651.4%	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Elevation Oncolo ELEV

$21.6M

Hoth Therapeutics Inc HOTH

$15.8M

Curis CRIS

$14.9M

Promis Neuroscie PMN

$32.8M

Citius Pharmaceuticals Inc CTXR

$17.1M

Frequently Asked Questions

What is Lisata Therapeutics Inc's annual revenue?

Lisata Therapeutics Inc (LSTA) reported $1.0M in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Lisata Therapeutics Inc profitable?

No, Lisata Therapeutics Inc (LSTA) reported a net income of -$20.0M in fiscal year 2024, with a net profit margin of -1998.5%.

What is Lisata Therapeutics Inc's earnings per share (EPS)?

Lisata Therapeutics Inc (LSTA) reported diluted earnings per share of $-2.40 for fiscal year 2024. This represents a 7.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Lisata Therapeutics Inc's EBITDA?

Lisata Therapeutics Inc (LSTA) had EBITDA of -$22.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Lisata Therapeutics Inc's operating margin?

Lisata Therapeutics Inc (LSTA) had an operating margin of -2240.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Lisata Therapeutics Inc's net profit margin?

Lisata Therapeutics Inc (LSTA) had a net profit margin of -1998.5% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Lisata Therapeutics Inc's operating cash flow?

Lisata Therapeutics Inc (LSTA) generated -$19.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Lisata Therapeutics Inc's total assets?

Lisata Therapeutics Inc (LSTA) had $35.0M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Lisata Therapeutics Inc spend on research and development?

Lisata Therapeutics Inc (LSTA) invested $11.3M in research and development during fiscal year 2024.

How many shares does Lisata Therapeutics Inc have outstanding?

Lisata Therapeutics Inc (LSTA) had 8M shares outstanding as of fiscal year 2024.

What is Lisata Therapeutics Inc's current ratio?

Lisata Therapeutics Inc (LSTA) had a current ratio of 6.16 as of fiscal year 2024, which is generally considered healthy.

What is Lisata Therapeutics Inc's debt-to-equity ratio?

Lisata Therapeutics Inc (LSTA) had a debt-to-equity ratio of 0.19 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lisata Therapeutics Inc's return on assets (ROA)?

Lisata Therapeutics Inc (LSTA) had a return on assets of -57.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Lisata Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Lisata Therapeutics Inc (LSTA) had $16.2M in cash against an annual operating cash burn of $19.4M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Lisata Therapeutics Inc's Piotroski F-Score?

Lisata Therapeutics Inc (LSTA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lisata Therapeutics Inc's earnings high quality?

Lisata Therapeutics Inc (LSTA) has an earnings quality ratio of 0.97x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.